SURPASS-2: investing ADP-A2M4CD8 SPEAR T-cell therapy to treat esophageal and GEJ cancers

SURPASS: Mechanism of action of ADP-A2M4CD8Подробнее

CAR-T cells versus SPEAR T-cells to treat solid tumorsПодробнее

ADP-A2M4CD8 Mechanism of Action (Next-generation SPEAR T-cell)Подробнее

Adaptimmune SPEAR T-Cell Mechanism of Action VideoПодробнее

SURPASS: ADP-A2M4CD8 T-cell receptor T-cell therapy and pembrolizumab in UCПодробнее

SURPASS: ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapyПодробнее

SURPASS: evaluating the next-generation of SPEAR T-cell therapyПодробнее

Adaptimmune: SPEAR T-cellsПодробнее

AdaptimmuneПодробнее

Proton therapy may be effective for treating esophageal cancer in elderly - U.S.A NewsПодробнее

BASECAMP-1: progress in developing CAR-T cell therapy for solid tumorsПодробнее

LB1908: a novel CAR-T cell therapy targeting claudin 18.2 in GI malignanciesПодробнее

AdaptimmuneПодробнее

Update on Adaptimmune's SURPASS Family of TrialsПодробнее

SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLSПодробнее

Дмитрий Черепащук: Валютные пары под давлениемПодробнее

The End of Cancer? CAR T-Cell Therapy & the Biology RevolutionПодробнее

Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ CancerПодробнее

Adaptimmune Therapeutics shares update on its late-stage clinical pipeline assets to treat cancerПодробнее